Galderma’s Announcement Regarding NEMLUVIO (New Long Term Data Presentation in Atopic Dermatitis)

TOKYO, June 9, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma (SIX: GALD) issued a news release regarding presentation of the results of two-year data from a new interim analysis of the ARCADIA long-term extension study of NEMLUVIO ® (nemolizumab) in moderate-to-severe atopic dermatitis, at the Revolutionizing Atopic Dermatitis (RAD) Conference. NEMLUVIO is a humanized anti-human IL-31 receptor A monoclonal antibody created by Chugai. Clinical development and marketing of NEMLUVIO outside Japan is being conducted by Galderma. Please refer to the link below for details of the Galderma’s news release: RAD 2025: Long-term data on Nemluvio ® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years https://www.galderma.com/news/rad-2025-nemluvio Trademarks used or mentioned in this release are protected by laws.

The release as fetched from its publisher. chugai-pharm.co.jp ↗